Can pharmacogenomic testing improve the selection and dosing of antidepressants in patients with MDD? In this episode, we explore the findings of the PRIME Care trial and discuss the clinical significance of these tests.  Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 49 Effect of Pharmacogenomic Testing for Drug–Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial  

Exploring Pharmacogenomic Testing in MDD

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health & Fitness

In this episode, we dive into the diagnosis of fibromyalgia, a common nociplastic pain syndrome. We explore how to assess widespread pain and associated symptoms and how to understand fibromyalgia as a spectrum rather than a binary diagnosis. How can this nuanced approach help us tailor treatment strategies?  Faculty: Daniel Clauw, M.D. Host: Richard Seeber, M.D.  Learn more about our memberships here Earn 0.75 CME: Nociplastic Pain Syndromes: Focus on Fibromyalgia Diagnosing Fibromyalgia 

Beyond the Pain: Diagnosing Fibromyalgia

In this episode, we delve into the potential for irreversible sexual dysfunction after SSRI use, based on a large-scale Israeli study. Could a few months or even days of antidepressant treatment lead to permanent erectile issues? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 55 Risk of Irreversible Post‑SSRI Sexual Dysfunction With Antidepressants 

Informed Consent and SSRIs: Discussing the Risk of Irreversible Sexual Side Effects

In this episode, we discuss the management of common adverse effects associated with clozapine treatment, including myocarditis, cardiomyopathy, tachycardia, orthostatic hypotension, and metabolic syndrome. How can clinicians mitigate these risks while optimizing treatment outcomes for patients with treatment-resistant schizophrenia?  Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.  Learn more about our memberships here Earn 1.25 CME: Clozapine: Management and Challenges Managing Cardiac and Metabolic Adverse Effects of Clozapine 

Mastering Clozapine: Adverse Effect Management

In this episode, we explore relapse prevention strategies for youth with depression and anxiety disorders. Are there effective ways to reduce the risk and prolong the time to relapse? Dr. David Rosenberg discusses the findings of a recent meta-analysis and systematic review on this crucial topic. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 15 Relapse Prevention Strategies for Depression and Anxiety in Remitted Youth 

Preventing Depression and Anxiety Relapse in Youth

In this episode, we navigate the complexities of initiating and optimizing clozapine treatment for patients with treatment-resistant schizophrenia. How do you chart the course for successful clozapine therapy while managing side effects and drug interactions? Join us as Dr. Brian Miller shares his expertise and valuable psychopharmacology pearls. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.  Learn more about our memberships here Earn 1.25 CMEs: Clozapine: Management and Challenges Initiating and Optimizing Clozapine 

Exploring Pharmacogenomic Testing in MDD

Download our free app to listen on your phone